Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126 · see citing works

Stress and the brain: from adaptation to disease

de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621 · see citing works

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965 · see citing works

Characterization of a 41-Residue Ovine Hypothalamic Peptide that Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904 · see citing works

Stress and Depression

Hammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979 · see citing works

Causal Relationship Between Stressful Life Events and the Onset of Major Depression

Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,486 · see citing works

The Corticosteroid Receptor Hypothesis of Depression

Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181 · see citing works

Animal models of neuropsychiatric disorders

Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · see citing works

The link between childhood trauma and depression: insights from HPA axis studies in humans

Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704 · see citing works

Peptidergic neurones

Hökfelt, T. G. M., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,552 · see citing works

The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami

Carraway, R. E., & Leeman, S. E. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43429-7 · Cited by 1,543 · see citing works

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders

Raison, C. L., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1554 · Cited by 1,197 · see citing works

Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey

Molnar, B. E., Buka, S. L., & Kessler, R. C. (2001) · American Journal of Public Health · doi:10.2105/ajph.91.5.753 · Cited by 1,193 · see citing works

Dynamic DNA methylation programs persistent adverse effects of early-life stress

Murgatroyd, C., Patchev, A. V., Wu, Y., Micale, V., Bockmühl, Y., Fischer, D., Holsboer, F., Wotjak, C. T., Almeida, O. F. X., & Spengler, D. (2009) · Nature Neuroscience · doi:10.1038/nn.2436 · Cited by 1,162 · see citing works

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Kramer, M. S., Cutler, N. R., Feighner, J. P., Shrivastava, R. K., Carman, J. S., Sramek, J. J., Reines, S. A., Liu, G. F., Snavely, D. B., Wyatt-Knowles, E. S., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071 · see citing works

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · see citing works

Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression

Chalmers, D., Lovenberg, T. W., & Souza, E. D. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06340.1995 · Cited by 925 · see citing works

Clinical Characteristics of Women With a History of Childhood Abuse: Unhealed Wounds

McCauley, J. (1997) · JAMA · doi:10.1001/jama.1997.03540410040028 · Cited by 904 · see citing works

A Potent Nonpeptide Antagonist of the Substance P (NK 1 ) Receptor

Snider, R. M., Constantine, J. W., Lowe, J. A., III, Longo, K. P., Lebel, W. S., Woody, H. A., Drozda, S. E., Desai, M. C., Vinick, F. J., Spencer, R. W., et al. (1991) · Science · doi:10.1126/science.1703323 · Cited by 859 · see citing works

Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation

HOLSBOER, F., & Barden, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 851 · see citing works

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705 · see citing works

Neuropsychopharmacology

Mathur, R. (2004) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10243_6 · Cited by 669 · see citing works

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654 · see citing works

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.

Coplan, J. D., Andrews, M. W., Rosenblum, L. A., Owens, M. J., Friedman, S., Gorman, J. M., & Nemeroff, C. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1619 · Cited by 649 · see citing works

Influence of Child Abuse on Adult Depression: Moderation by the Corticotropin-Releasing Hormone Receptor Gene

Bradley, R. G., Binder, E. B., Epstein, M. P., Tang, Y., Nair, H. P., Liu, W., Gillespie, C. F., Berg, T., Evces, M., Newport, D. J., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.26 · Cited by 643 · see citing works

Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age

Antoni, F. A. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1004 · Cited by 636 · see citing works

Receptors and antagonists for substance P and related peptides.

Regoli, D. C., Boudon, A., & Fauchère, J. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06810-3 · Cited by 633 · see citing works

Regulation of pituitary ACTH secretion during chronic stress

Aguilera, G. (1994) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1994.1013 · Cited by 557 · see citing works

Structure and functional expression of the cloned rat neurotensin receptor

Tanaka, K., Masu, M., & Nakanishi, S. (1990) · Neuron · doi:10.1016/0896-6273(90)90137-5 · Cited by 537 · see citing works

The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum

de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 524 · see citing works

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

Reul, J. M. H. M. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00117-5 · Cited by 515 · see citing works

Neuropeptide S

Xu, Y.-L., Reinscheid, R. K., Huitrón‐Reséndiz, S., Clark, S. D., Wang, Z., Lin, S. H., Brücher, F., Zeng, J., Ly, N. K., Henriksen, S. J., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.005 · Cited by 510 · see citing works

Molecular cloning and expression of a rat Via arginine vasopressin receptor

Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477 · see citing works

Stress Hormone Regulation: Biological Role and Translation into Therapy

Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473 · see citing works

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V _1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · see citing works

Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress

Müller, M. B., Zimmermann, S., Sillaber, I., Hagemeyer, T. P., Deussing, J. M., Timpl, P., Kormann, M., Droste, S. K., Kühn, R., Reul, J. M. H. M., et al. (2003) · Nature Neuroscience · doi:10.1038/nn1123 · Cited by 446 · see citing works

Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice

Elliott, E., Ezra-Nevo, G., Regev, L., Neufeld-Cohen, A., & Chen, A. (2010) · Nature Neuroscience · doi:10.1038/nn.2642 · Cited by 436 · see citing works

A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptor

Emonds‐Alt, X., Vilain, P., Goulaouic, P., Proietto, V., Broeck, D. V., Advenier, C., Naline, E., Neliat, G., Fur, G. L., & Brelière, J. C. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90352-p · Cited by 434 · see citing works

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression

Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433 · see citing works

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S. J., WEBSTER, E. L., Atkinson, A. J., Schulkin, J. A., Contoreggi, C. S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6079 · Cited by 404 · see citing works

Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors

Ivy, A. S., Rex, C. S., Chen, Y., Dubé, C., Maras, P. M., Grigoriadis, D. E., Gall, C. M., Lynch, G., & Baram, T. Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1784-10.2010 · Cited by 402 · see citing works

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Holmes, A., Heilig, M. A., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 401 · see citing works

Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders

Souza, E. B. D. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00011-9 · Cited by 397 · see citing works

The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor

Mazella, J., Zsürger, N., Navarro, V., Chabry, J., Kaghad, M., Caput, D., Ferrara, P., Vita, N., Gully, D., Maffrand, J., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26273 · Cited by 391 · see citing works

Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression

Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M. C., Kohli, M., et al. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.017 · Cited by 381 · see citing works

The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease

LANG, R., Gundlach, A. L., & Kofler, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.009 · Cited by 376 · see citing works

Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation

Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375 · see citing works

Contribution of life events to causation of psychiatric illness

Paykel, E. S. (1978) · Psychological Medicine · doi:10.1017/s003329170001429x · Cited by 372 · see citing works

International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

Hauger, R. L., Grigoriadis, D. E., Dallman, M. F., Plotsky, P. M., Vale, W., & Dautzenberg, F. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.3 · Cited by 365 · see citing works

Combined Dexamethasone/Corticotropin Releasing Hormone Test Predicts Treatment Response in Major Depression–A Potential Biomarker?

Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · see citing works

Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets

Hauger, R., Risbrough, V. B., Brauns, O., & Dautzenberg, F. M. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706777950684 · Cited by 341 · see citing works

Extrapituitary expression of the rat V1b vasopressin receptor gene.

Lolait, S. J., O’Carroll, A., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, É., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337 · see citing works

Neuropeptides: opportunities for drug discovery

Hökfelt, T. G. M., Bartfai, T., & Bloom, F. E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00482-4 · Cited by 333 · see citing works

Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder

Meltzer, H. Y., Arvanitis, L. A., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330 · see citing works

Neuropsychopharmacology

Stolerman, I. P. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_4410 · Cited by 322 · see citing works

Glutamatergic and Dopaminergic Neurons Mediate Anxiogenic and Anxiolytic Effects of CRHR1

Refojo, D., Schweizer, M. C., Kühne, C., Ehrenberg, S., Thoeringer, C. K., Vogl, A. M., Dedic, N., Schumacher, M., von Wolff, G., Avrabos, C., et al. (2011) · Science · doi:10.1126/science.1202107 · Cited by 313 · see citing works

Comparative Distribution of Vasopressin V1b and Oxytocin Receptor Messenger Ribonucleic Acids in Brain ¹

Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308 · see citing works

Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression

van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306 · see citing works

The role of substance P in stress and anxiety responses

Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 304 · see citing works

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · see citing works

Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus

Caffé, A. R., van Leeuwen, F. W., & Luiten, P. G. M. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902610206 · Cited by 286 · see citing works

Protective Effect of CRHR1 Gene Variants on the Development of Adult Depression Following Childhood Maltreatment: Replication and Extension

Polanczyk, G., Caspi, A., Williams, B., Price, T. S., Danese, A., Sugden, K., Uher, R., Poulton, R., & Moffitt, T. E. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.114 · Cited by 285 · see citing works

Mushroom bodies of the cockroach: Their participation in place memory

Mizunami, M., Weibrecht, J. M., & Strausfeld, N. J. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19981228)402:4 · Cited by 284 · see citing works

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential

Striepens, N., Kendrick, K. M., Maier, W., & Hurlemann, R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.07.001 · Cited by 283 · see citing works

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

Rupniak, N. M. J., & Kramer, M. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01396-6 · Cited by 278 · see citing works

The combined dexamethasone/CRH test as a potential surrogate marker in depression

Ising, M., Kunzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 268 · see citing works

Therapeutic potential of neuropeptide Y (NPY) receptor ligands

Brothers, S. P., & Wahlestedt, C. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000100 · Cited by 268 · see citing works

Behavioral Consequences of Intracerebral Vasopressin and Oxytocin: Focus on Learning and Memory **This paper is dedicated to our friend and scientific teacher Prof. Dr Armin Ermisch (1935–1995).

Engelmann, M., Wotjak, C. T., Neumann, I. D., Ludwig, M., & Landgraf, R. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00059-3 · Cited by 267 · see citing works

Molecular cloning of a levocabastine‐sensitive neurotensin binding site

Chalon, P., Vita, N., Kaghad, M., Guillemot, M., Bonnin, J., Delpech, B., Fur, G. L., Ferrara, P., & Caput, D. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00397-3 · Cited by 267 · see citing works

Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity

Tyrka, A. R., Price, L. H., Gelernter, J., Schepker, C., Anderson, G. M., & Carpenter, L. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.012 · Cited by 264 · see citing works

Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin-releasing hormone signaling

Chen, Y., Rex, C. S., Rice, C. J., Dubé, C. M., Gall, C. M., Lynch, G., & Baram, T. Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003825107 · Cited by 256 · see citing works

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH ₁ Antagonist) in the Treatment of Major Depression

Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · see citing works

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer, M. S., Winokur, A., Kelsey, J. E., Preskorn, S., Rothschild, A. J., Snavely, D. B., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D. J., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 254 · see citing works

Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress

Brunson, K. L., Eghbal-Ahmadi, M., Bender, R., Chen, Y., & Baram, T. Z. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151224898 · Cited by 236 · see citing works

SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor

Emonds‐Alt, X., Bichon, D., Ducoux, J.-P., Héaulme, M., Miloux, B., Poncelet, M., Proietto, V., Broeck, D. V., Vilain, P., Neliat, G., et al. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00413-m · Cited by 217 · see citing works

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211 · see citing works

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents

Perrault, G., Griebel, G., & Sanger, D. J. (1998) · Psychopharmacology · doi:10.1007/s002130050645 · Cited by 210 · see citing works

Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo

Furmark, T., Appel, L., Michelgård, Å., Wahlstedt, K., Åhs, F., Zancan, S., Jacobsson, E., Flyckt, K., Grohp, M., Bergström, M., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.029 · Cited by 206 · see citing works

Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat

van Leeuwen, F., & Caffé, R. (1983) · Cell and Tissue Research · doi:10.1007/bf00211473 · Cited by 206 · see citing works

Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – Findings from the Munich Antidepressant Response Signature (MARS) project

Hennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S. M., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 191 · see citing works

Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.

Behan, D. P., Grigoriadis, D. E., Lovenberg, T. W., Chalmers, D. T., Heinrichs, S. C., Liaw, C. W., & Souza, E. B. D. (1996) · PubMed · Cited by 191 · see citing works

Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder

Altemus, M. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820010009002 · Cited by 186 · see citing works

The Role of Corticotropin-Releasing Factor in the Pathogenesis of Major Depression

Nemeroff, C. B. (1988) · Pharmacopsychiatry · doi:10.1055/s-2007-1014652 · Cited by 185 · see citing works

Cholecystokinin antagonists: Pharmacological and therapeutic potential

Herranz, R. (2003) · Medicinal Research Reviews · doi:10.1002/med.10042 · Cited by 184 · see citing works

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans

Dong, C., Wong, M.-L., & Licinio, J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.92 · Cited by 182 · see citing works

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment

Papiol, S., Arias, B., Gastó, C., Gutiérrez, B., Catalán, R., & Fañanás, L. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.017 · Cited by 181 · see citing works

How can we realize the promise of personalized antidepressant medicines?

Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177 · see citing works

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

Coric, V., Feldman, H., Oren, D. A., Shekhar, A., Pultz, J. A., Dockens, R. C., Wu, X., Gentile, K. A., Huang, S.-P., Emison, E., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20695 · Cited by 172 · see citing works

Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression

Zhou, J.-N., Riemersma, R. F., Unmehopa, U. A., Hoogendijk, W. J. G., van Heerikhuize, J. J., Hofman, M. A., & Swaab, D. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.655 · Cited by 172 · see citing works

Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?

Griebel, G. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00041-2 · Cited by 171 · see citing works

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

Licinio, J., O'Kirwan, F., Irizarry, K. J. L., Merriman, B., Thakur, S., Jepson, R., Lake, S. L., Tantisira, K. G., Weiss, S. T., & Wong, M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001587 · Cited by 168 · see citing works

Forebrain CRF1Modulates Early-Life Stress-Programmed Cognitive Deficits

Wang, X., Rammes, G., Kraev, I., Wolf, M., Liebl, C., Scharf, S. H., Rice, C. J., Wurst, W., Holsboer, F., Deussing, J. M., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2259-11.2011 · Cited by 156 · see citing works

Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects

von Bardeleben, U., Holsboer, F., Stalla, G. K., & Müller, O. A. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90480-1 · Cited by 153 · see citing works

Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression

Liu, Z., Zhu, F., Wang, G., Xiao, Z., Wang, H., Tang, J., Wang, X., Qiu, D.-S., Liu, W., Cao, Z., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.016 · Cited by 149 · see citing works

In Quest of Identifying Vulnerability Markers for Psychiatric Disorders by All-Night Polysomnography

Lauer, C. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140063009 · Cited by 147 · see citing works

High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response

Ising, M., Zimmermann, U. S., Kunzel, H. E., Uhr, M., Foster, A. C., Learned, S. M., Holsboer, F., & Grigoriadis, D. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301328 · Cited by 143 · see citing works

Localization of Vasopressin (V_1a) Receptor Binding and mRNA in the Rhesus Monkey Brain

Young, Toloczko, & Insel (1999) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1999.00332.x · Cited by 139 · see citing works

Evidence for a Role of the Supraopticohypophyseal System in Regulation of Adrenocorticotropic Secretion

McCann, S. M., & Brobeck, J. R. (1954) · Experimental Biology and Medicine · doi:10.3181/00379727-87-21368 · Cited by 139 · see citing works

The Effects of Deleting the Mouse Neurotensin Receptor NTR1 on Central and Peripheral Responses to Neurotensin

Pettibone, D. J., Hess, J. F., Hey, P. J., Jacobson, M. A., Leviten, M. W., Lis, E. V., Mallorga, P. J., Pascarella, D. M., Snyder, M. A., Williams, J. B., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.305 · Cited by 138 · see citing works

Neurotensin: Role in psychiatric and neurological diseases

Cáceda, R., Kinkead, B. L., & Nemeroff, C. B. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.024 · Cited by 129 · see citing works

Localization of neuropeptide receptor mRNA in rat brain: Initial observations using probes for neurotensin and substance P receptors

Elde, R., Schalling, M., Ceccatelli, S., Nakanishi, S., & Hökfelt, T. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90187-e · Cited by 128 · see citing works

The involvement of the vasopressin system in stress-related disorders

Landgraf, R. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359664 · Cited by 127 · see citing works

Encyclopedia of Psychopharmacology

Baumann, P. (2010) · Springer eBooks · doi:10.1007/978-3-642-27772-6 · Cited by 127 · see citing works

NK3 receptor antagonists: the next generation of antipsychotics?

Spooren, W. P. J. M., Riemer, C., & Meltzer, H. Y. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1905 · Cited by 124 · see citing works

Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression

Held, K., Kunzel, H. E., Ising, M., Schmid, D. A., Zobel, A. W., Murck, H., Holsboer, F., & Steiger, A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00076-1 · Cited by 123 · see citing works

Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders

Ebner, K., Sartori, S. B., & Singewald, N. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168074 · Cited by 121 · see citing works

The Gerbil Elevated Plus-maze II Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00313-5 · Cited by 120 · see citing works

Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter

Spengler, D., Rupprecht, R., Phi‐van, L., & Holsboer, F. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.11.1480179 · Cited by 120 · see citing works

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 116 · see citing works

Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder

Keck, M. E., Kern, N., Erhardt, A., Unschuld, P. G., Ising, M., Salyakina, D., Müller, M. B., Knorr, C. C., Lieb, R., Hohoff, C., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30750 · Cited by 113 · see citing works

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415

Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112 · see citing works

Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep

Kimura, M., Müller-Preuss, P., Lu, A., Wiesner, E., Flachskamm, C., Wurst, W., Holsboer, F., & Deussing, J. M. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.46 · Cited by 111 · see citing works

Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response

Binder, E. B., Owens, M. J., Liu, W., Deveau, T. C., Rush, A. J., Trivedi, M. H., D, M. F. M., Bradley, B., Ressler, K. J., & Nemeroff, C. B. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.18 · Cited by 111 · see citing works

Childhood maltreatment, the corticotropin‐releasing hormone receptor gene and adult depression in the general population

Grabe, H. J., Schwahn, C., Appel, K., Mahler, J., Schulz, A., Spitzer, C., Fenske, K., Barnow, S., Lucht, M. J., Freyberger, H. J., et al. (2010) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31131 · Cited by 111 · see citing works

Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor

Gehlert, D. R., Shekhar, A., Morin, S. M., Hipskind, P. A., Zink, C., Gackenheimer, S. L., Shaw, J., Fitz, S. D., & Sajdyk, T. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.030 · Cited by 110 · see citing works

Substance P Receptor Antagonists in Psychiatry

Herpfer, I., & Lieb, K. (2005) · CNS Drugs · doi:10.2165/00023210-200519040-00001 · Cited by 108 · see citing works

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig

Marco, N., Thirion, A., Mons, G., Bougault, I., Fur, G. L., Soubrié, P., & Steinberg, R. (1998) · Neuropeptides · doi:10.1016/s0143-4179(98)90075-0 · Cited by 104 · see citing works

Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas

Refojo, D., Echenique, C., Müller, M. B., Reul, J. M. H. M., Deussing, J. M., Wurst, W., Sillaber, I., Páez-Pereda, M., Holsboer, F., & ARZT, E. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502070102 · Cited by 103 · see citing works

Quality of Life of Adolescents With Perceived Disabilities

Edwards, T. C. (2003) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsg011 · Cited by 99 · see citing works

Transient Early-Life Forebrain Corticotropin-Releasing Hormone Elevation Causes Long-Lasting Anxiogenic and Despair-Like Changes in Mice

Kolber, B. J., Boyle, M. P., Wieczorek, L., Kelley, C. L., Onwuzurike, C., Nettles, S. A., Vogt, S. K., & Muglia, L. J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4470-09.2010 · Cited by 94 · see citing works

Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function

Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Fur, G. L., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29250-8 · Cited by 93 · see citing works

Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety

Keck, M. E. (2006) · Amino Acids · doi:10.1007/s00726-006-0333-y · Cited by 92 · see citing works

The Gerbil Elevated Plus-Maze I Behavioral Characterization and Pharmacological Validation

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00312-3 · Cited by 87 · see citing works

Intranasally Administered Neuropeptide S (NPS) Exerts Anxiolytic Effects Following Internalization Into NPS Receptor-Expressing Neurons

Ionescu, I. A., Dine, J., Yen, Y.-C., Buell, D. R., Herrmann, L., Holsboer, F., Eder, M., Landgraf, R., & Schmidt, U. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.317 · Cited by 87 · see citing works

Highly potent neurotensin analog that causes hypothermia and antinociception

Tyler-McMahon, B. M., Stewart, J. A., Fariñas, F., McCormick, D., & Richelson, E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00877-8 · Cited by 86 · see citing works

Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody

Fassio, A., Evans, G., Grisshammer, R., Bolam, J. P., Mimmack, M. L., & Emson, P. C. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00060-5 · Cited by 86 · see citing works

Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

Griebel, G., Stemmelin, J., Gal, C. S., & Soubrié, P. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764797 · Cited by 84 · see citing works

Species differences in tachykinin receptor distribution: Further evidence that the substance P (NK1) receptor predominates in human brain

Rigby, M., O’Donnell, R., & Rupniak, N. M. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20664 · Cited by 78 · see citing works

Melanin-Concentrating Hormone MCH1 Receptor Antagonists

Shimazaki, T., Yoshimizu, T., & Chaki, S. (2006) · CNS Drugs · doi:10.2165/00023210-200620100-00002 · Cited by 73 · see citing works

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs

Gobbi, G., & Blier, P. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.032 · Cited by 72 · see citing works

A 25 year adventure in the field of tachykinins

Beaujouan, J., Torrens, Y., Saffroy, M., Kemel, M. L., & Glowinski, J. (2004) · Peptides · doi:10.1016/j.peptides.2004.02.011 · Cited by 72 · see citing works

Trillion-dollar brain drain

Smith, K. (2011) · Nature · doi:10.1038/478015a · Cited by 71 · see citing works

Desmopressin Normalizes the Blunted Adrenocorticotropin Response to Corticotropin-Releasing Hormone in Melancholic Depression: Evidence of Enhanced Vasopressinergic Responsivity

Dinan, T. G., Lavelle, E., Scott, L. V., Newell-Price, J. D. C., Medbak, S., & Grossman, A. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5723 · Cited by 70 · see citing works

In vitro binding and CNS effects of novel neurotensin agonists that cross the blood–brain barrier

Tyler, B. M., Douglas, C. L., Fauq, A. H., Pang, Y., Stewart, J. A., Cusack, B. M., McCormick, D., & Richelson, E. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00011-8 · Cited by 70 · see citing works

Cerebrospinal Fluid Vasopressin—Changes in Depression

Gjerris, A., Vendsborg, P. B., HAMMER, M., Christensen, N. J., & Rafaelsen, O. J. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.147.6.696 · Cited by 69 · see citing works

Binding of the Non-Peptide Vasopressin V1a Receptor Antagonist SR-49059 in the Rat Brain: An in vitro and in vivo Autoradiographic Study

Tribollet, E., Raufaste, D., Maffrand, J., & Gal, C. S. (1999) · Neuroendocrinology · doi:10.1159/000054409 · Cited by 66 · see citing works

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

Ratti, E., Bellew, K. M., Bettica, P. U., Bryson, H., Zamuner, S., Archer, G. E., Squassante, L., Bye, A., Trist, D. G., Krishnan, K. R. R., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823608ca · Cited by 64 · see citing works

Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging

Gründer, G., Hiemke, C., Paulzen, M., Veselinovic, T., & Vernaleken, I. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286282 · Cited by 62 · see citing works

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

Louis, C., Stemmelin, J., Boulay, D., Bergis, O. E., Cohen, C., & Griebel, G. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.10.020 · Cited by 59 · see citing works

Effects of SR48968, a selective non-peptide NK 2 receptor antagonist on emotional processes in rodents

Griebel, G., Perrault, G., & Soubrié, P. (2001) · Psychopharmacology · doi:10.1007/s002130100830 · Cited by 57 · see citing works

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

Tauscher, J. T., Kielbasa, W., Iyengar, S., Vandenhende, F., Peng, X., Mozley, D. P., Gehlert, D. R., & Marek, G. J. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.10.005 · Cited by 56 · see citing works

A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial

Mathew, S. J., Vythilingam, M., Murrough, J. W., Zarate, C. A., Feder, A., Luckenbaugh, D. A., Kinkead, B. L., Parides, M. K., Trist, D. G., Bani, M., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.012 · Cited by 55 · see citing works

Neuropeptides in Psychiatric Diseases: An Overview with a Particular Focus on Depression and Anxiety Disorders

Surget, A., Leman, S., Griebel, G., Belzung, C., & Yalçın, İ. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359682 · Cited by 52 · see citing works

Neurotensin Agonists

Boules, M., Shaw, A. M., Fredrickson, P. A., & Richelson, E. (2007) · CNS Drugs · doi:10.2165/00023210-200721010-00002 · Cited by 49 · see citing works

The Orphanin FQ/Nociceptin (OFQ/N) System

Civelli, O. (2008) · Springer eBooks · doi:10.1007/400_2007_057 · Cited by 49 · see citing works

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol

Liem-Moolenaar, M., Gray, F., de Visser, S. J., Franson, K. L., Schoemaker, R. C., Schmitt, J. A. J., Cohen, A., & van Gerven, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094524 · Cited by 42 · see citing works

Novel Treatments of Schizophrenia: Targeting the Neurotensin System

Kinkead, B. L., & Nemeroff, C. B. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359655 · Cited by 40 · see citing works

Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 – 2010)

Malherbe, P., Ballard, T. M., & Ratni, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.568482 · Cited by 38 · see citing works

Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges

Kronenberg, G., Berger, P., Tauber, R., Bandelow, B., Henkel, V., & Heuser, I. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837768 · Cited by 34 · see citing works

Pharmacokinetics of Novel Hexapeptides with Neurotensin Activity in Rats.

MACHIDA, R., Tokumura, T., TSUCHIYA, Y., SASAKI, A., & Kouichi, A. B. E. (1993) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.16.43 · Cited by 33 · see citing works

NK ₁ receptor antagonism and emotional processing in healthy volunteers

Chandra, P., Hafizi, S., Massey-Chase, R., Goodwin, G., Cowen, P., & Harmer, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103101 · Cited by 30 · see citing works

Dose Response of Arginine Vasopressin to the CCK-B Agonist Pentagastrin

Abelson, J. L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00182-2 · Cited by 30 · see citing works

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

Griebel, G., & Beeské, S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.007 · Cited by 29 · see citing works

Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia

Dawson, L. A., & Smith, P. W. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210790170067 · Cited by 29 · see citing works

Is bigger better for depression trials?

Liu, K. S., Snavely, D. B., Ball, W. A., Lines, C. R., Reines, S. A., & Potter, W. Z. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.07.003 · Cited by 28 · see citing works

The Melanin-Concentrating Hormone (MCH) System Modulates Behaviors Associated with Psychiatric Disorders

Chung, S., Verheij, M. M. M., Hesseling, P., van Vugt, R. W. M., Buell, M. R., Belluzzi, J. D., Geyer, M. A., Martens, G. J. M., & Civelli, O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019286 · Cited by 27 · see citing works

NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers

McCabe, C., Cowen, P. J., & Harmer, C. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990150 · Cited by 27 · see citing works

Characterization of a novel and selective V1B receptor antagonist

Craighead, M. W., Milne, R. J., Campbell-Wan, L., WATSON, L., Presland, J. P., THOMSON, F. J., Marston, H. M., & MacSweeney, C. P. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00440-8 · Cited by 25 · see citing works

PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density?

Sullivan, G. M., Parsey, R. V., Kumar, J. S. D., Arango, V., Kassir, S. A., Huang, Y.-Y., Simpson, N. R., Heertum, R. L. V., & Mann, J. J. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.01.012 · Cited by 25 · see citing works

Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties

Boules, M., McMahon, B. M., Warrington, L. E., Stewart, J. A., Jackson, J. G., Fauq, A. H., McCormick, D., & Richelson, E. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02981-x · Cited by 25 · see citing works

Structure, development, and maintenance of the nerve net of the body column in hydra

Sakaguchi, M., Mizusina, A., & Kobayakawa, Y. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960909)373:1 · Cited by 24 · see citing works

Restriction of HIV-1 Replication in Monocytes Is Abolished by Vpx of SIVsmmPBj

Schüle, S., Kloke, B., Kaiser, J. K., Heidmeier, S., Panitz, S., Wolfrum, N., Cichutek, K., & Schweizer, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007098 · Cited by 23 · see citing works

Discontinued psychiatric drugs in 2008

Kirchhoff, V., Nguyen, H. T., Soczynska, J. K., Woldeyohannes, H. O., & McIntyre, R. S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903184591 · Cited by 22 · see citing works

Developing Small Molecule Nonpeptidergic Drugs for the Treatment of Anxiety Disorders: Is the Challenge Still Ahead?

Steckler, T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_14 · Cited by 21 · see citing works

Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state.

Tokumura, T., TANAKA, T., SASAKI, A., TSUCHIYA, Y., Kouichi, A. B. E., & Machida, R. (1990) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.38.3094 · Cited by 21 · see citing works

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

Overstreet, D. H., Naimoli, V., & Griebel, G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.006 · Cited by 19 · see citing works

Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.

Simonsen, K. B., Juhl, K., Steiniger‐Brach, B., & Nielsen, S. M. (2010) · PubMed · Cited by 19 · see citing works

Short-term NK1 receptor antagonism and emotional processing in healthy volunteers

Pringle, A., McTavish, S. F., Williams, C., Smith, R., Cowen, P. J., & Harmer, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2133-z · Cited by 18 · see citing works

Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment

Paslakis, G., Luppa, P. B., Gilles, M., Kopf, D., Weber-Hamann, B., Lederbogen, F., & Deuschle, M. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.11.015 · Cited by 17 · see citing works

Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system

Lu, A., Steiner, M. A., Whittle, N., Vogl, A. M., Walser, S. M., Ableitner, M., Refojo, D., Ekker, M., Rubenstein, J. L. R., Stalla, G. K., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.107 · Cited by 17 · see citing works

Talnetant GlaxoSmithKline.

Evangelista, S. (2005) · PubMed · Cited by 15 · see citing works

Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons

Michaud, J.-C., Gueudet, C., & Soubrié, P. (2000) · Neuroreport · doi:10.1097/00001756-200005150-00017 · Cited by 13 · see citing works

Identification of a new series of non-peptidic NK3 receptor antagonists

Juhl, K., Hansen, T., Kehler, J., Khanzhin, N. A., Nørgaard, M. B., Ruhland, T., Larsen, D. B., Jensen, K. G., Steiniger‐Brach, B., Nielsen, S. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.135 · Cited by 7 · see citing works

[Neurotensin, a multi-action peptide hormone].

St-Pierre, S. A., Quirion, R., Regoli, D. C., Gervais, A., Lavigne, F., Poirier, A., JOLICOEUR, F. B., Barbeau, A., & Rioux, F. (1980) · PubMed · Cited by 4 · see citing works

Überlegungen zur Wirksamkeit von Psychopharmaka

Leucht, S., Heres, S., & Davis, J. M. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3349-9 · Cited by 3 · see citing works

Tachykinins

Turiault, M., Cohen, C., & Griebel, G. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_210 · Cited by 3 · see citing works

Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors

Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954 · see citing works

Structure of the agonist-bound neurotensin receptor

White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 511 · see citing works

Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement

Koob, G. F. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.023 · Cited by 477 · see citing works

HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation

Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450 · see citing works

Detecting Activated Cell Populations Using Single-Cell RNA-Seq

Wu, Y. E., Pan, L., Zuo, Y., Li, X., & Hong, W. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.026 · Cited by 438 · see citing works

50 years of hurdles and hope in anxiolytic drug discovery

Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 414 · see citing works

Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development

Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337 · see citing works

Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq–based resource for pain and sensory neuroscience research

Ray, P. R., Torck, A., Quigley, L. D., Wangzhou, A., Neiman, M., Rao, C., Lam, T., Kim, J., Kim, T. H., Zhang, M. Q., et al. (2018) · Pain · doi:10.1097/j.pain.0000000000001217 · Cited by 330 · see citing works

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways

López‐Giménez, J. F., & González‐Maeso, J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_478 · Cited by 311 · see citing works

The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress

Zelikowsky, M., Hui, M., Karigo, T., Choe, A., Yang, B., Blanco, M. R., Beadle, K., Gradinaru, V., Deverman, B. E., & Anderson, D. J. (2018) · Cell · doi:10.1016/j.cell.2018.03.037 · Cited by 282 · see citing works

The Corticotropin-Releasing Factor Family: Physiology of the Stress Response.

Deussing, J., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 234 · see citing works

Region-specific roles of the corticotropin-releasing factor–urocortin system in stress

Henckens, M. J. A. G., Deussing, J. M., & Chen, A. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.94 · Cited by 245 · see citing works

The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions

Dunlop, B. W., & Wong, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.010 · Cited by 245 · see citing works

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders

Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works

Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli

Egloff, P., Hillenbrand, M., Klenk, C., Batyuk, A., Heine, P., Balada, S. B., Schlinkmann, K. M., Scott, D. J., Schütz, M., & Plückthun, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317903111 · Cited by 212 · see citing works

Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice

Peters, S., Slattery, D. A., Uschold‐Schmidt, N., Reber, S. O., & Neumann, I. D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.01.021 · Cited by 180 · see citing works

Emerging drugs for the treatment of anxiety

Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 168 · see citing works

Are We Getting Closer to Valid Translational Models for Major Depression?

Berton, O., Hahn, C.-G., & Thase, M. E. (2012) · Science · doi:10.1126/science.1222940 · Cited by 148 · see citing works

β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors

Slosky, L. M., Bai, Y., Tóth, K., Ray, C., Rochelle, L. K., Badea, A., Chandrasekhar, R., Pogorelov, V. M., Abraham, D., Atluri, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.053 · Cited by 147 · see citing works

The neurobiological correlates of childhood adversity and implications for treatment

Tyrka, A. R., Burgers, D. E., Philip, N. S., Price, L. H., & Carpenter, L. L. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12143 · Cited by 142 · see citing works

Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness

Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139 · see citing works

Cryo-EM structure of an activated GPCR–G protein complex in lipid nanodiscs

Zhang, M., Gui, M., Wang, Z., Gorgulla, C., Yu, J. J., Wu, H., Sun, Z.-Y. J., Klenk, C., Merklinger, L., Morstein, L., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-00554-6 · Cited by 122 · see citing works

Biophysical characterization of membrane proteins in nanodiscs

Inagaki, S., Ghirlando, R., & Grisshammer, R. (2012) · Methods · doi:10.1016/j.ymeth.2012.11.006 · Cited by 115 · see citing works

Brain galanin system genes interact with life stresses in depression-related phenotypes

Juhász, G., Hullám, G., Eszlári, N., Gonda, X., Antal, P., Anderson, I. M., Hökfelt, T. G. M., Deakin, J. F. W., & Bagdy, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403649111 · Cited by 107 · see citing works

Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects?

Belzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106 · see citing works

Structural prerequisites for G-protein activation by the neurotensin receptor

Krumm, B. E., White, J. F., Shah, P., & Grisshammer, R. (2015) · Nature Communications · doi:10.1038/ncomms8895 · Cited by 101 · see citing works

Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice

Zhang, R., Asai, M., Mahoney, C. E., Joachim, M., Shen, Y., Gunner, G., & Majzoub, J. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.136 · Cited by 97 · see citing works

Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder

Dunlop, B. W., Binder, E. B., Iosifescu, D., Mathew, S. J., Neylan, T. C., Pape, J. C., Carrillo-Roa, T., Green, C., Kinkead, B., Grigoriadis, D., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.024 · Cited by 96 · see citing works

Evidence for the role of corticotropin-releasing factor in major depressive disorder

Waters, R. P., Rivalan, M., Bangasser, D. A., Deussing, J. M., Ising, M., Wood, S. K., Holsboer, F., & Summers, C. H. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.011 · Cited by 93 · see citing works

Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention

Xie, J. Y., Felice, M. D., Kopruszinski, C. M., Eyde, N., LaVigne, J. E., Remeniuk, B., Hernandez, P., Yue, X., Goshima, N., Ossipov, M. H., et al. (2017) · Cephalalgia · doi:10.1177/0333102417702120 · Cited by 87 · see citing works

Endocrinology and the brain: corticotropin-releasing hormone signaling

Inda, C., Armando, N. G., Claro, P. A. D. S., & Silberstein, S. (2017) · Endocrine Connections · doi:10.1530/ec-17-0111 · Cited by 77 · see citing works

Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala

Kim, T.-K., Kim, J., Park, J. Y., Lee, J. E., Choi, J., Kim, H., Lee, E. H., Kim, S.-W., Lee, J.-K., Kang, H., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.004 · Cited by 75 · see citing works

Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease

Lundh, S. H., Nilsson, N., Soylu-Kucharz, R., Kirik, D., & Petersén, Å. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt203 · Cited by 74 · see citing works

Hippocampal neurogenesis: a biomarker for depression or antidepressant effects? Methodological considerations and perspectives for future research

Tanti, A., & Belzung, C. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1612-z · Cited by 71 · see citing works

Structure and dynamics of a constitutively active neurotensin receptor

Krumm, B. E., Lee, S., Bhattacharya, S., Botos, I., White, C. F., Du, H., Vaidehi, N., & Grisshammer, R. (2016) · Scientific Reports · doi:10.1038/srep38564 · Cited by 71 · see citing works

Ethological concepts enhance the translational value of animal models

Peters, S. M., Pothuizen, H. H. J., & Spruijt, B. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.043 · Cited by 70 · see citing works

Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?

Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 70 · see citing works

Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences

Grillon, C., Robinson, O. J., Cornwell, B., & Ernst, M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0445-1 · Cited by 65 · see citing works

Neuroscience-driven discovery and development of sleep therapeutics

Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63 · see citing works

The Biology of Vasopressin

Sparapani, S., Millet-Boureima, C., Oliver, J., Mu, K., Hadavi, P., Kalostian, T., Ali, N., Avelar, C. M., Bardies, M., Barrow, B., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010089 · Cited by 63 · see citing works

Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs

Ong, J. J. Y., Wei, D. Y., & Goadsby, P. J. (2018) · Drugs · doi:10.1007/s40265-018-0865-y · Cited by 60 · see citing works

Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide

Barde, S. S., Rüegg, J., Prud’homme, J., Ekström, T. J., Palkovits, M., Turecki, G., Bagdy, G., Ihnatko, R., Theodorsson, E., Juhász, G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617824113 · Cited by 58 · see citing works

Anxiogenic and Stressor Effects of the Hypothalamic Neuropeptide RFRP-3 Are Overcome by the NPFFR Antagonist GJ14

Kim, J. S., Brownjohn, P. W., Dyer, B. S., Beltramo, M., Walker, C. S., Hay, D. L., Painter, G. F., Tyndall, J. D. A., & Anderson, G. M. (2015) · Endocrinology · doi:10.1210/en.2015-1532 · Cited by 57 · see citing works

Leading compounds for the validation of animal models of psychopathology

Micale, V., Kučerová, J., & Šulcová, A. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1692-9 · Cited by 57 · see citing works

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 56 · see citing works

Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.

Buckley, M. M., O’Mahony, S. M., & O’Malley, D. (2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8846 · Cited by 55 · see citing works

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators

Pinkerton, A. B., Peddibhotla, S., Yamamoto, F., Slosky, L. M., Bai, Y., Maloney, P., Hershberger, P., Hedrick, M. P., Falter, B., Ardecky, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00340 · Cited by 54 · see citing works

Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders

Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 53 · see citing works

Role of Corticotropin Releasing Factor in the Neuroimmune Mechanisms of Depression: Examination of Current Pharmaceutical and Herbal Therapies

Jiang, Y., Peng, T., Gaur, U., Silva, M., Little, P. J., Chen, Z., Qiu, W., Zhang, Y., & Zheng, W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00290 · Cited by 53 · see citing works

Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray

Wang, P., Li, H., Barde, S. S., Zhang, M., Sun, J., Wang, T., Zhang, P., Luo, H., Wang, Y., Yang, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609198113 · Cited by 51 · see citing works

A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: An fMRI study

Lee, R. J., Coccaro, E. F., Cremers, H., McCarron, R., Lu, S.-F., Brownstein, M. J., & Simon, N. G. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00100 · Cited by 50 · see citing works

Biological substrates underpinning diagnosis of major depression

Sibille, E. L., & French, B. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000436 · Cited by 50 · see citing works

The Role of Neuropeptides in Suicidal Behavior: A Systematic Review

Serafini, G., Pompili, M., Lindqvist, D., Dwivedi, Y. K., & Girardi, P. (2013) · BioMed Research International · doi:10.1155/2013/687575 · Cited by 49 · see citing works

Discovery of ML314, a Brain Penetrant Nonpeptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor

Peddibhotla, S., Hedrick, M. P., Hershberger, P., Maloney, P., Li, Y., Milewski, M., Gosalia, P., Gray, W., Mehta, A., Sugarman, E. D., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400176n · Cited by 47 · see citing works

The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle

Grillon, C., Hale, E., Lieberman, L., Davis, A., Pine, D. S., & Ernst, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.316 · Cited by 47 · see citing works

Neuropeptides and oligopeptidases in schizophrenia

Rodríguez, B., Nani, J. V. S., Almeida, P. G. C., Brietzke, E. M., Lee, R. S., & Hayashi, M. A. F. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.024 · Cited by 47 · see citing works

DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder

Pape, J. C., Carrillo‐Roa, T., ROTHBAUM, B. O., Nemeroff, C. B., Czamara, D., Zannas, A. S., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Mayberg, H. S., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0569-x · Cited by 45 · see citing works

Crystal structure of the human NK 1 tachykinin receptor

Yin, J., Chapman, K., Clark, L. D., Shao, Z., Borek, D., Xu, Q., Wang, J., & Rosenbaum, D. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812717115 · Cited by 45 · see citing works

ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse

Barak, L. S., Bai, Y., Peterson, S. M., Evron, T., Urs, N. M., Peddibhotla, S., Hedrick, M. P., Hershberger, P., Maloney, P., Chung, T. D. Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00291 · Cited by 44 · see citing works

Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543

Dournes, C., Beeské, S., Belzung, C., & Griebel, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.019 · Cited by 44 · see citing works

Neurokinin receptor antagonism: a patent review (2014-present)

Muñoz, M., & Coveñas, R. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1769599 · Cited by 41 · see citing works

Bright Fluorescence Monitoring System Utilizing Zoanthus sp. Green Fluorescent Protein (ZsGreen) for Human G-Protein-Coupled Receptor Signaling in Microbial Yeast Cells

Nakamura, Y., Ishii, J., & Kondo, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082237 · Cited by 40 · see citing works

Neuropeptide Systems and Schizophrenia

LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39 · see citing works

Distinct populations of corticotropin-releasing factor (CRF) neurons mediate divergent yet complementary defensive behaviors in response to a threat

Chudoba, R., & Dabrowska, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109461 · Cited by 37 · see citing works

Therapeutic approaches targeting the neurotensin receptors

Iyer, M. R., & Kunos, G. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1866539 · Cited by 37 · see citing works

Vasopressin V1B receptor antagonists as potential antidepressants

Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34 · see citing works

Structural Dynamics and Thermostabilization of Neurotensin Receptor 1

Lee, S., Bhattacharya, S., Tate, C. G., Grisshammer, R., & Vaidehi, N. (2015) · The Journal of Physical Chemistry B · doi:10.1021/jp510735f · Cited by 34 · see citing works

Corticotropin-releasing factor peptide antagonists: Design, characterization and potential clinical relevance

Rivier, J., & RIVIER, C. L. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.10.006 · Cited by 33 · see citing works

SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands

Huber, S., Casagrande, F., Hug, M. N., Wang, L., Heine, P., Kummer, L., Plückthun, A., & Hennig, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175842 · Cited by 32 · see citing works

The diverse role of corticotropin-releasing factor (CRF) and its CRF1 and CRF2 receptors under pathophysiological conditions: Insights into stress/anxiety, depression, and brain injury processes

Domin, H., & Śmiałowska, M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105748 · Cited by 31 · see citing works

Blood-brain barrier transport kinetics of the neuromedin peptides NMU, NMN, NMB and NT

Gevaert, B., Wynendaele, E., Stalmans, S., Bracke, N., D’Hondt, M., Smolders, I. J., Eeckhaut, A. V., & Spiegeleer, B. M. J. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.051 · Cited by 29 · see citing works

Orphan neuropeptides and receptors: Novel therapeutic targets

Fricker, L. D., & Devi, L. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.006 · Cited by 29 · see citing works

Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation

Dim, N., Perepelyuk, M., Gomes, O., Thangavel, C., Liu, Y., Den, R. B., Lakshmikuttyamma, A., & Shoyele, S. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0124-2 · Cited by 27 · see citing works

Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries

Ranganathan, A., Heine, P., Rudling, A., Plückthun, A., Kummer, L., & Carlsson, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00646 · Cited by 27 · see citing works

DrosophilaTachykininergic Neurons Modulate the Activity of Two Groups of Receptor-Expressing Neurons to Regulate Aggressive Tone

Wohl, M. P., Liu, J., & Asahina, K. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1734-22.2023 · Cited by 26 · see citing works

Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons

Barde, S. S., Benitez, J. A., Zhong, W., Solarz, A., Mei, I., Prud’homme, J., Palkovits, M., Turecki, G., Mulder, J., Uhlén, M., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.09.004 · Cited by 26 · see citing works

Neuroendocrine Regulation of Anxiety: Beyond the Hypothalamic‐Pituitary‐Adrenal Axis

Borrow, A. P., Stranahan, A. M., Suchecki, D., & Yunes, R. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12403 · Cited by 26 · see citing works

Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A–E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium

Al‐Awadhi, F. H., Gao, B., Rezaei, M. A., Kwan, J. C., Li, C., Ye, T., Paul, V. J., & Luesch, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00885 · Cited by 24 · see citing works

Differential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression

Xu, F., Yang, H. J., Chen, J., Wu, Q., Gong, W., Zhang, J., Shao, W., Mu, J., Yang, D., Yang, Y., et al. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0543-y · Cited by 23 · see citing works

Examining the Role of Vasopressin in the Modulation of Parental and Sexual Behaviors

Zimmermann-Peruzatto, J. M., Lazzari, V. M., de Moura, A. C., Almeida, S., & Giovenardi, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00130 · Cited by 23 · see citing works

Identification of a Role for the Ventral Hippocampus in Neuropeptide S-Elicited Anxiolysis

Dine, J., Ionescu, I. A., Stepan, J., Yen, Y.-C., Holsboer, F., Landgraf, R., Eder, M., & Schmidt, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060219 · Cited by 23 · see citing works

Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436

Katz, D. A., Liu, W., Locke, C. S., Dutta, S., & Tracy, K. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4089-5 · Cited by 23 · see citing works

Understanding and Predicting Antidepressant Response: Using Animal Models to Move Toward Precision Psychiatry

Herzog, D. P., Beckmann, H., Lieb, K., Ryu, S., & Müller, M. B. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00512 · Cited by 23 · see citing works

MiRNA mimic screen for improved expression of functional neurotensin receptor from HEK 293 cells

Xiao, S., Chen, Y., Betenbaugh, M. J., Martin, S. E., & Shiloach, J. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25567 · Cited by 22 · see citing works

Stress Impacts the Regulation Neuropeptides in the Rat Hippocampus and Prefrontal Cortex

Li, W., Papilloud, A., Lozano‐Montes, L., Zhao, N., Ye, X., Zhang, X., Sandi, C., & Rainer, G. (2018) · PROTEOMICS · doi:10.1002/pmic.201700408 · Cited by 22 · see citing works

Neurotensin and Dynorphin Bi-Directionally Modulates CeA Inhibition of oval BNST Neurons in Male Mice

Normandeau, C. P., Torruella-Suárez, M. L., Sarret, P., McElligott, Z. A., & Dumont, É. C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.031 · Cited by 22 · see citing works

The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and d-cycloserine

Philbert, J., Belzung, C., & Griebel, G. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3020-1 · Cited by 22 · see citing works

Human fear acquisition deficits in relation to genetic variants of the corticotropin‐releasing hormone receptor 1 and the serotonin transporter — revisited

Heitland, I., Groenink, L., van Gool, J. M. G., Domschke, K., Reif, A., & Baas, J. M. P. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12276 · Cited by 21 · see citing works

Neuroimmune Cross Talk in the Gut. Neuroendocrine and neuroimmune pathways contribute to the pathophysiology of irritable bowel syndrome

O’Malley, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00272.2016 · Cited by 21 · see citing works

Molecular Plasticity of the Nucleus Accumbens Revisited—Astrocytic Waves Shall Rise

Kardos, J., Dobolyi, Á., Szabó, Z. M., Simon, Á., Lourmet, G. S., Palkovits, M., & Héja, L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1641-z · Cited by 21 · see citing works

Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance

Rees, C. L., White, C. M., & Ascoli, G. A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170414163506 · Cited by 20 · see citing works

Activation Dynamics of the Neurotensin G Protein-Coupled Receptor 1

Cong, X., Fiorucci, S., & Golebiowski, J. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00216 · Cited by 20 · see citing works

Stress-Related Brain Neuroinflammation Impact in Depression: Role of the Corticotropin-Releasing Hormone System and P2X7 Receptor

Silberstein, S., Liberman, A. C., Claro, P. A. D. S., Ugo, M. B., Deussing, J. M., & ARZT, E. S. (2021) · NeuroImmunoModulation · doi:10.1159/000515130 · Cited by 19 · see citing works

Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder

Hodgins, G. E., Blommel, J. G., Dunlop, B. W., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Mayberg, H. S., & Harvey, P. D. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000858 · Cited by 19 · see citing works

A polymorphism in the Crhr1 gene determines stress vulnerability in male mice.

Labermaier, C., Kohl, C., Hartmann, J., Devigny, C., Altmann, A., Weber, P., Arloth, J., Quast, C., Wagner, K., Scharf, S. H., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1986 · Cited by 20 · see citing works

Indications of success: Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development

Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 19 · see citing works

Neuroendocrine and Neurochemical Processes in Depression

Cowen, P. J. (2015) · Psychopathology Review · doi:10.5127/pr.034513 · Cited by 18 · see citing works

The Nucleus Accumbens CRH–CRHR1 System Mediates Early-Life Stress-Induced Sleep Disturbance and Dendritic Atrophy in the Adult Mouse

Wang, T., Ma, Y., Zhang, C., Liu, X., Sun, Y., Wang, H., Wang, H., Zhong, Y.-H., Su, Y., Li, J., et al. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00903-z · Cited by 18 · see citing works

A cleavable ligand column for the rapid isolation of large quantities of homogeneous and functional neurotensin receptor 1 variants from E. coli

Egloff, P., Deluigi, M., Heine, P., Balada, S. B., & Plückthun, A. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.10.006 · Cited by 18 · see citing works

Peripheral Biomarkers in Animal Models of Major Depressive Disorder

Carboni, L. (2013) · Disease Markers · doi:10.1155/2013/284543 · Cited by 17 · see citing works

The Role of Peptides in Treatment of Psychiatric Disorders

Holsboer, F. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6_2 · Cited by 36 · see citing works

Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins

Griebel, G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605105859 · Cited by 7 · see citing works

Clinical trials of neuropeptides in psychiatric disorders.

(1982) · PubMed

Neuropeptides in Psychiatry

Suchak, V., Sathyanath, S., & Kakunje, A. (2022) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_91_22 · Cited by 12 · see citing works

Neuropeptide Systems and Schizophrenia

LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39 · see citing works